(Q33519113)

English

Controversies in the treatment of high-risk prostate cancer--what is the optimal combination of hormonal therapy and radiotherapy: a review of literature

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

27 July 2017

1 reference

Europe PubMed Central

Controversies in the treatment of high-risk prostate cancer--what is the optimal combination of hormonal therapy and radiotherapy: a review of literature (English)

1 reference

Europe PubMed Central

27 July 2017

radiation therapy

0 references

author name string

Abrahim Al-Mamgani

1

1 reference

Europe PubMed Central

27 July 2017

Joos V Lebesque

2

1 reference

Europe PubMed Central

27 July 2017

Wilma D Heemsbergen

3

1 reference

Europe PubMed Central

27 July 2017

Lisa Tans

4

1 reference

Europe PubMed Central

27 July 2017

Wim J Kirkels

5

1 reference

Europe PubMed Central

27 July 2017

Peter C Levendag

6

1 reference

Europe PubMed Central

27 July 2017

Luca Incrocci

7

1 reference

Europe PubMed Central

27 July 2017

publication date

1 May 2010

1 reference

Europe PubMed Central

27 July 2017

1 reference

Europe PubMed Central

27 July 2017

70

1 reference

Europe PubMed Central

27 July 2017

7

1 reference

Europe PubMed Central

27 July 2017

701-709

1 reference

Europe PubMed Central

27 July 2017

Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21102

21 January 2018

A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21102

21 January 2018

Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21102

21 January 2018

Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21102

21 January 2018

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21102

21 January 2018

Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21102

21 January 2018

Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21102

21 January 2018

Identifiers

10.1002/PROS.21102

1 reference

Europe PubMed Central

27 July 2017

1 reference

Europe PubMed Central

27 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33519113&oldid=1976417996"